Philogen S.p.a.
Clinical trials sponsored by Philogen S.p.a., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to reignite immune attack on Hard-to-Treat cancers Results expected Dec 2026 (estimated)
-
New hope for brain cancer patients: drug combo targets aggressive tumors
Disease control OngoingThis study tests a combination of two drugs, L19TNF and lomustine, in 90 adults whose glioblastoma has returned or worsened. The goal is to find the safest and most effective dose to control the tumor and extend survival. Participants must have confirmed glioblastoma and be in ad…
Phase 2 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
RA injection study pulled before it even started
Symptom relief CancelledThis study aimed to test the safety of a new drug called F8IL10, given as a joint injection every 4 weeks for 8 weeks, in people with rheumatoid arthritis who still have joint flares despite standard treatments. The goal was to find the safest dose. However, the study was withdra…
Phase 1 • Sponsor: Philogen S.p.A. • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC